With the ground bro­ken on a Van­cou­ver head­quar­ters, an­ti­body mak­er Ab­Cellera will add man­u­fac­tur­ing space next door

The Cana­di­an gov­ern­ment is look­ing to raise the pro­file of the coun­try’s na­tive biotech in­dus­try, and British Co­lum­bia’s Ab­Cellera is the lat­est com­pa­ny to ben­e­fit from the na­tion’s strate­gic in­no­va­tion fund.

Ab­Cellera has land­ed a site in Van­cou­ver for a 130,000-square-foot fa­cil­i­ty to help bring the biotech’s an­ti­body ther­a­pies to clin­i­cal tri­als. In April, the com­pa­ny broke ground on a 380,000-square-foot head­quar­ters that will be with­in walk­ing dis­tance of the new man­u­fac­tur­ing fa­cil­i­ty, set to be built on a va­cant two-acre site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER